First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors

20254 citationsJournal Articlehybrid Open Access

Authors

Timothy A. Yap · The University of Texas MD Anderson Cancer Center

Olivier Rixe · University of New Mexico

Capucine Baldini · Institut Gustave Roussy

Ursa Brown‐Glaberman · University of New Mexico

Sergey Efuni · Kyowa Kirin (France)

David S. Hong · The University of Texas MD Anderson Cancer Center

Christophe Massard

Abstract

KHK2455 + mogamulizumab was safe and well tolerated with manageable toxicities, and resulted in dose-dependent suppression of IDO1 activity; signals of antitumor activity were observed.

Topics & Keywords

Tryptophan and brain disorders Cancer-related cognitive impairment studies Bipolar Disorder and Treatment

Publication Details

Published in: Cancer

Volume 131, Issue 13, pp. e35939-e35939

DOI: 10.1002/cncr.35939

Field-Weighted Citation Impact: 2.31

Command Palette

First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors

Authors

Abstract

Topics & Keywords

Publication Details